Structures by: McGregor P. A.
Total: 25
Paracetamol monomethanolate
C9H13N1O3
Chemical Communications (Cambridge, United Kingdom) (2003) 24 3004-3005
a=7.630(2)Å b=17.209(3)Å c=7.3710(11)Å
α=90° β=115.52(3)° γ=90°
Sulfuric acid
H2SO4
Journal of the Chemical Society, Dalton Transactions (2002) 8 1867
a=7.695(13)Å b=4.559(7)Å c=8.378(3)Å
α=90° β=107.42(8)° γ=90°
Paracetamol monomethanolate
C9H13N1O3
Chemical Communications (Cambridge, United Kingdom) (2003) 24 3004-3005
a=7.630(2)Å b=17.209(3)Å c=7.3710(11)Å
α=90° β=115.52(3)° γ=90°
Paracetamol hemi-dimethylpiperazine
2[C8H9NO2][C6H14N2]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=10.6970(9)Å b=11.0240(9)Å c=9.4896(8)Å
α=90.00° β=100.684(2)° γ=90.00°
Paracetamol hemi(N-Methylmorpholine)
2[C8H9NO2][C5H11NO]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=10.5749(8)Å b=11.0221(8)Å c=9.3894(7)Å
α=90.00° β=101.145(2)° γ=90.00°
Paracetamol hemi-piperazine
2[C8H9NO2][C4H10N2]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=15.893(5)Å b=5.1664(17)Å c=12.993(4)Å
α=90.00° β=113.633(5)° γ=90.00°
2[C8H9NO2][C4H9NO]
2[C8H9NO2][C4H9NO]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=7.2791(9)Å b=14.6277(18)Å c=18.303(2)Å
α=90.00° β=90.00° γ=90.00°
Paracetamol hemi-dioxane
2[C8H9O2N],[C4H8O2]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=12.421(5)Å b=12.056(4)Å c=13.396(3)Å
α=90.00° β=91.51(3)° γ=90.00°
C4H10O
C4H10O
Acta Crystallographica, Section B (2006) 62, 4 599-605
a=17.55(2)Å b=17.55(2)Å c=8.080(10)Å
α=90.00° β=90.00° γ=120.00°
C4H10O
C4H10O
Acta Crystallographica Section B (2006) 62, 4 599-605
a=18.0946(13)Å b=18.0946(13)Å c=8.4041(9)Å
α=90.00° β=90.00° γ=120.00°
C4H10O
C4H10O
Acta Crystallographica, Section B (2006) 62, 4 599-605
a=6.2027Å b=9.1431Å c=14.7554Å
α=86.373° β=78.776° γ=76.363°
C4H10O
C4H10O
Acta Crystallographica, Section B (2006) 62, 4 599-605
a=17.4389Å b=17.4389Å c=8.0210Å
α=90° β=90° γ=120°
C4H10O
C4H10O
Acta Crystallographica, Section B (2006) 62, 4 599-605
a=17.5898Å b=17.5898Å c=8.1014Å
α=90° β=90° γ=120°
Isopropyl cyclohexane
C9H18
Acta Crystallographica Section E (2002) 58, 6 o652-o655
a=15.689(8)Å b=5.298(3)Å c=10.641(6)Å
α=90° β=101.790(10)° γ=90°
C20H52N12O20
C20H52N12O20
Inorganic Chemistry (2004) 43, 8023-8029
a=11.596(3)Å b=11.803(6)Å c=14.575(7)Å
α=89.86(5)° β=83.68(5)° γ=64.05(4)°
C20H55Cu2N10O17.5
C20H55Cu2N10O17.5
Inorganic Chemistry (2004) 43, 8023-8029
a=24.863(6)Å b=18.046(10)Å c=15.977(13)Å
α=90.00° β=96.93(5)° γ=90.00°
Alpha glycine
C2H5N1O2
Crystal Growth & Design (2005) 5, 4 1415
a=4.9669(9)Å b=11.459(4)Å c=5.4231(12)Å
α=90° β=114.916(15)° γ=90°
Alpha glycine
C2H5N1O2
Crystal Growth & Design (2005) 5, 4 1415
a=4.8690(7)Å b=11.139(3)Å c=5.3777(10)Å
α=90° β=116.888(11)° γ=90°
Gamma glycine
C2H5N1O2
Crystal Growth & Design (2005) 5, 4 1415
a=6.9332(6)Å b=6.9332(6)Å c=5.4552(8)Å
α=90° β=90° γ=120°
Gamma Glycine
C2H5N1O2
Crystal Growth & Design (2005) 5, 4 1415
a=6.8617(4)Å b=6.8617(4)Å c=5.4282(6)Å
α=90° β=90° γ=120°
Delta glycine
C2H5N1O2
Crystal Growth & Design (2005) 5, 4 1415
a=11.156(4)Å b=5.8644(11)Å c=5.3417(17)Å
α=90° β=125.83(4)° γ=90°
Epsilon glycine
C2H5N1O2
Crystal Growth & Design (2005) 5, 4 1415
a=4.8887(10)Å b=5.7541(11)Å c=5.4419(11)Å
α=90° β=116.682(10)° γ=90°
Paracetamol-bipyridine
[C8H9NO2][C10H8N2]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=11.2906(10)Å b=24.103(2)Å c=11.5526(10)Å
α=90.00° β=96.1484(16)° γ=90.00°
PhOH
PhOH
Acta Crystallographica Section B (2002) 58, 6 1018-1024
a=11.610(4)Å b=5.4416(11)Å c=12.217(5)Å
α=90.00° β=101.47(3)° γ=90.00°
C4H10O
C4H10O
Acta Crystallographica, Section B (2006) 62, 4 599-605
a=6.0631Å b=9.0661Å c=14.4494Å
α=85.248° β=78.531° γ=75.800°